Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,372 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Doxorubicin Hydrochloride Clear all
Completed Phase 1 Interventional

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

NCT00020748
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

NCT02186834
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Liposomal doxorubicin, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 7, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

NCT02420847
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
Interventions
Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 7, 2026, 5:58 AM EDT
Terminated Phase 1 Interventional

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 7, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

NCT01990352
View directory record Official record
Conditions
Breast Cancer
Interventions
Pegylated liposomal doxorubicin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Tucson, Arizona • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 7, 2026, 5:58 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

NCT00562185
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, doxorubicin hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

NCT00635050
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Doxil, Paclitaxel, Cyclophosphamide, Avastin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

NCT00577993
View directory record Official record
Conditions
Lymphoma
Interventions
Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 76 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 7, 2026, 5:58 AM EDT
Withdrawn Phase 2 Interventional

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT01670084
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Phase II Bevacizumab + Tax In Advanced Breast Cancer

NCT00027885
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, cyclophosphamide, docetaxel, doxorubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Cleveland, Ohio • Middleburg Heights, Ohio • Orange, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Older Adults With Acute Lymphoblastic Leukemia

NCT00973752
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Prednisone, Vincristine, Doxorubicin, PEG-asparaginase, Cytarabine, Methotrexate, Imatinib, Clofarabine, 6 Mercaptopurine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
51 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 7, 2026, 5:58 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
634
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 7, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional

Doxil and Gemcitabine in Recurrent Ovarian Cancer

NCT00312650
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
liposomal doxorubicin and gemcitabine
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

NCT00238368
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 7, 2026, 5:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stage I/II Nasal NK Cell Lymphoma

NCT01321008
View directory record Official record
Conditions
Lymphoma
Interventions
Radiation, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Not applicable Interventional

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

NCT00346125
View directory record Official record
Conditions
Sarcoma
Interventions
pegfilgrastim, doxorubicin hydrochloride, ifosfamide, pegylated liposomal doxorubicin hydrochloride, conventional surgery, fludeoxyglucose F 18
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 7, 2026, 5:58 AM EDT
Suspended Phase 2 Interventional

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

NCT06738368
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
Drug · Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 7, 2026, 5:58 AM EDT
Terminated Not applicable Interventional Results available

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

NCT02147301
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization
Interventions
LC Bead
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

NCT00003334
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
Interventions
paclitaxel, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
New York, New York • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 7, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

NCT02710734
View directory record Official record
Conditions
Urothelial Carcinoma of the Bladder
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Intensity modulated radiation therapy (IMRT), Transurethral Resection of Bladder tumor, 5-FU, Mitomycin C
Drug · Radiation · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions
Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 7, 2026, 5:58 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
257
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 5:58 AM EDT